patients with relapsed or refractory IGL received intensified preparative therapy and underwent autologous transplantation at a single institution. Two intensified preparative regimens were used: cyclophosphamide, etoposide, total body irradiation (CY-VP-TBI) (n = 66) and cyclophosphamide, BCNU, etoposide (CBV) (n = 33). As clinical features and results were not different for the two preparative regimens, results were combined. For all patients undergoing autologous transplantation, 5-year actuarial overall survival (OS) was 34% ± 6%; 5-year event-free survival (EFS) was 26% ± 5%. For patients who responded to primary therapy, salvage therapy, or both, OS was 42% ± 7%; for nonresponders to prior therapy, OS was 14% ± 7%, P Ͻ 0.025. OS was better among patients responding to salvage therapy (50% ± 9%), than among patients who had a complete response to initial therapy, but failed to respond or were untested/unevaluable with respect to salvage therapy (26% ± 10%; P Ͻ 0.025). On multivariate analysis, response to salvage therapy was associated with survival following autologous transplantation (P Ͻ 0.005). Treatment related mortality was 9% overall and only 6% after G-CSF and GM-CSF were introduced into routine clinical practice. High-intensity preparative therapy is highly effective, with acceptable treatmentrelated mortality, in patients with IGL who have responded to induction therapy, salvage therapy, or both. The best responses are observed in patients responding to salvage therapy. Randomized prospective studies will be needed to further define the role of intensified preparative regimens. Bone Marrow Transplantation (2000) Intensification of the preparative regimen is one potential means of improving these clinical results.
preparative regimens, long-term disease-free survival (DFS) has been associated with disease chemoresponsiveness. [3] [4] [5] [6] [7] However, even among patients with sensitive disease, long-term DFS has generally been seen in only 30-50% of patients. 2, [5] [6] [7] [8] Among patients with resistant disease, less than 10% survive long-term. 3, 6 Intensification of the preparative regimen is one potential means of improving these clinical results. [9] [10] [11] [12] Since 1986, we have studied two intensified preparative regimens in patients with relapsed or refractory IGL. One regimen added etoposide to the standard cyclophosphamide-TBI regimen, the other used augmented dose BCNU in combination with etoposide and cyclophosphamide. This report summarizes our experience with augmented preparative therapy in patients with relapsed or refractory IGL undergoing autologous transplantation.
Patients and methods

Patients and eligibility
Records of all patients who received autologous stem cell transplantation (ASCT) at Vanderbilt University Medical Center or the affiliated Nashville Veteran's Affairs Hospital between September 1986 and June 1998 were reviewed. Patients were included in the study if both the initial and the most recent pathological material prior to transplantation were interpreted as IGL. Following review by two of the authors (WRM, TLM) at the time this report was prepared, patients with low-grade NHL evolving to IGL prior to transplantation were excluded from this analysis as were patients with high-grade lymphoma and patients with mantle cell lymphoma.
Patients with IGL were eligible for ASCT if they had primary refractory disease or had relapsed following initial standard chemotherapy. Patients were generally seen at the time of first relapse. However, treatment with multiple prior regimens did not exclude patients from consideration for ASCT. Patients were eligible for ASCT if the bone marrow biopsy done immediately before the planned transplant did not reveal microscopic involvement with NHL. Patients with prior bone marrow involvement were eligible, as were patients whose pre-transplant bone marrow specimens were positive only by detection of the bcl-2 gene rearrangement or by detection of a cytogenetic abnormality. The majority of patients in this study received autologous bone marrow as the source of stem cells. Patients whose bone marrow involvement prior to transplantation was detectable only by finding the bcl-2 gene rearrangement (two patients) or by cytogenetic analysis (one patient), and who received autologous marrow purged with etoposide and methylprednisolone, 13 were included in the analysis. To be eligible for transplantation, patients were required to have normal or nearly normal function of kidneys (serum creatinine Ͻ1.5 mg/dl), liver (serum bilirubin Ͻ2.0 mg/dl), lungs (corrected carbon monoxide diffusion capacity Ͼ50% of predicted value) and heart (left ventricular ejection fraction Ͼ50%). All patients were antibody negative for HIV and HTLV-1.
During the early part of the study (1986) (1987) (1988) (1989) (1990) (1991) , patients with recurrent disease received either salvage chemotherapy, salvage radiation therapy, or went directly to transplantation. After January 1992, patients with recurrent disease generally received two cycles of platinum-based therapy such as DHAP 14 while awaiting transplantation, and underwent transplantation within a month of completing salvage chemotherapy. All patients were treated in accordance with Institutional Review Board approved protocols and gave written informed consent.
Preparative regimens
The intensified preparative regimen used in all patients eligible to receive total body irradiation (TBI) was Cy-VP-TBI, ie etoposide 1800 mg/m 2 by continuous infusion over 26 h, starting day −7, cyclophosphamide 150 mg/kg total dose (50 mg/kg, over 2 h, days −6, −5 and −4), and total body irradiation, five or six fractions of 200 cGy each, delivered on days −3, −2 and −1. Patients who received extensive prior radiotherapy, or who could not receive total body irradiation, received CBV, ie etoposide 2400 mg/m 2 by continuous infusion over 34 h, starting day −7, cyclophosphamide 1800 mg/m 2 days −6, −5, −4, and −3, and BCNU 400 mg/m 2 day −2.
Supportive care
All patients were treated in high efficiency particulate air filtered rooms. Vigorous hydration and mesna were administered at the time of cyclophosphamide infusion to prevent hemorrhagic cystitis. Platelet transfusions were administered to keep the platelet count above 20 × 10 9 /l. Red cell transfusions were administered to maintain the hematocrit above 25%. Use of growth factors was not uniform, as G-CSF and GM-CSF were not commercially available at the start of the study. Prophylactic acyclovir, fluconazole or low dose amphotericin B, and antibiotics were routinely administered.
Definitions of response to therapy prior to transplantation
Complete response (CR) to initial therapy (CR-1) was defined as disappearance of all clinical and radiological evidence of disease for a period of at least 3 months. Patients with a lesser response were considered to have not responded to primary therapy (NR-1). The duration of CR-1 was measured from the completion of initial chemotherapy.
Patients who received salvage therapy generally received only two cycles of salvage treatment prior to transplantation. A response to salvage therapy was therefore defined as a Ͼ50% response in all measurable disease with no single site showing progression during treatment. Patients meeting this criterion were categorized as R-2. Patients not meeting this response criterion were categorized as NR-2. Patients who did not receive salvage therapy, or whose response to salvage chemotherapy was not evaluable, were categorized as NE-2.
Response to autologous transplantation
Staging evaluations were performed prior to transplantation and within 2 months of transplantation. Complete response (CR) was defined as disappearance of all clinical and radiological evidence of disease. Patients whose only evidence following transplantation was minimal radiological evidence were considered CRs if the disease did not progress over a 3-month period. Administration of radiation therapy to a single area of possible stable residual disease was permitted and did not preclude classifying a patient as having a complete remission. Partial response (PR) was defined as a Ͼ50% response in all measurable disease with no single site showing progression.
Statistical considerations
End points included overall survival (OS; time from transplant to death or latest follow-up), and event-free survival (EFS; time from transplant to death, progression, or latest follow-up). For patients having less than a partial remission following transplantation, the event-free survival was defined as zero. All intervals were determined as of 1 January 1999. Survival curves were estimated by the KaplanMeier method. 15 Univariate and multivariate analyses of survival were conducted using the log rank method by means of NCSS 6.0 software. Comparisons of group composition were performed using either t-tests or chi-square tests.
Results
Patient characteristics
Characteristics of the 99 patients treated with autologous transplantation are presented in Table 1 . A preliminary analysis indicated that patients receiving the two preparative regimens (Cy-VP-TBI and CBV) did not differ with respect to age, sex, histologic type of NHL, stage at diagnosis, history of marrow involvement, source of stem cells, number of prior treatment regimens, OS and EFS. The only significant difference between the groups was that radiation therapy had been administered to 54% of the patients in the CBV group as compared to 14% in the CY-VP-TBI group, P Ͻ 0.0001, chi-square test (prior extensive radiation therapy was the major reason that patients received CBV rather than CY-VP-TBI). The groups were therefore combined for the analysis.
Response to intensified preparative therapy
Of the 99 patients undergoing autologous transplantation, 78 were evaluable for response. Twenty-one patients were 
Survival
Of the 99 patients undergoing autologous transplantation, 58 patients have died. Of the 41 patients who are still alive, median follow up is 31 months. The major cause of death was resistant or progressive lymphoma, which occurred in 48 patients. Nine patients died of treatment-related toxicity (9%). After the introduction of G-CSF and GM-CSF into clinical practice, treatment mortality fell from 14% to 6%, (P = 0.24, chi-square test). Seven of the nine deaths occurred before day +100 following transplantation. Five of these deaths were caused by infection, with fungi being the most common cause of fatal infection. One death was due to veno-occlusive disease of the liver, and one death was attributed to cardiac failure. Two treatment-related deaths occurred after day 100, and were due to pulmonary toxicity and associated infection. One death was due to a car accident which occurred while the patient was free of disease. No cases of myelodysplasia have been diagnosed in this patient population.
The relationship between survival and clinical characteristics of the patients undergoing autologous transplantation is shown in Table 2 . Median survival for the entire group was 22 months, with a 5-year actuarial survival of 34% ± 6%. Age, gender, stage at presentation, the use of prior radiation therapy, the prior use of high intensity-brief duration chemotherapy, 16 the use of CBV as compared to CY-VP-TBI, and the use of 1200 cGy as compared to 1000 cGy as the TBI dose were not significantly associated with survival following transplantation. There was a trend for patients with T cell lymphoma to have better survival following transplantation than patients with B cell lymphoma; 5-year OS 56% ± 18% vs 31% ± 6% (P = 0.06).
The quality of the response to primary and salvage chemotherapy was significantly associated with survival following autologous transplantation (Figure 1) . Patients who responded to either primary therapy, salvage therapy, or both had a median survival of 37 months with a 5-year actuarial OS of 42% ± 7%. Patients who did not respond to either initial therapy or salvage therapy had a median survival of 7 months with a 5-year actuarial OS of 14% ± 7% (P < 0.025).
To determine whether the response to initial therapy or the response to salvage therapy was more important in predicting survival following autologous transplantation, responders to prior therapy were stratified into separate groups (Table 3 ). This analysis showed that survival was significantly better in patients who responded to salvage therapy (regardless of the response to primary therapy) than in patients who responded to primary therapy but failed salvage therapy or were not evaluable for a response to salvage therapy (P Ͻ 0.025; Figure 2) . A multivariate analysis was also performed in which survival was the Figure 1 Survival among all patients undergoing autologous transplantation as related to whether or not the patients responded to initial therapy, salvage therapy, or both (responders) or failed to respond to either induction or salvage therapy (non-responders) (P < 0.025).
dependent variable and the independent variables were achieving CR with initial therapy, and achieving a response with salvage therapy. Achieving CR with initial therapy was not significantly related to survival (P = 0.42). However, responding to salvage therapy was highly significantly related to survival (P Ͻ 0.005). Obtaining CR following autologous transplantation was a necessary condition for achieving prolonged survival. Of the 42 complete responders, only 18 have died and median survival is 71 months. Of the partial responders, 21 of 26 are dead, with a median survival of 7 months. Eight of 10 non-responders are dead, with a median survival of 5 months.
Event-free survival
For patients undergoing autologous transplantation, 5-year actuarial EFS was 26% ± 5%. As with OS, EFS was superior in patients who were classified as responders to pre-transplant therapy (33% ± 7%) as compared to patients who were considered non-responders to pre-transplant therapy (14% ± 7%, P Ͻ 0.01). Among 51 patients who achi-261 Table 3 Survival as related to response to prior therapy among patients receiving intensified preparative regimens and autologous transplantation eved a CR following transplantation, 27 continue in CR (median duration 55 months), 20 have relapsed (of whom four are alive with disease), and four died of toxicity while in a documented CR. Considering only the patients who achieved a CR with autologous transplantation, EFS was 46% ± 8% (Figure 3 ).
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Discussion
High-dose cytotoxic therapy in conjunction with autologous stem cell transplantation is standard therapy for patients with relapsed intermediate grade non-Hodgkin's lymphoma (IGL), [1] [2] [3] [4] [5] and the superiority of this approach, as compared to salvage chemotherapy alone, has been documented in a randomized clinical trial. 17 In this study we attempted to improve the results achieved with autologous stem cell transplantation by employing intensified preparative therapy in 99 patients treated over a 10-year period.
For all patients undergoing autologous transplantation, 5-year actuarial OS was 34% ± 6%. As in previous studies, the factor most closely associated with improved survival following transplantation was the sensitivity of the tumor to therapy administered prior to transplantation. By both univariate and multivariate analyses, response to salvage therapy was the factor most significantly associated with survival.
There are two possible mechanisms by which a response to salvage therapy might be associated with improved survival. First, the response to salvage therapy might simply be identifying those patients whose tumors are sensitive to chemotherapy and who are likely to have good responses to high-dose therapy and autologous transplantation. Alternatively, by reducing the tumor burden, salvage therapy might contribute to the overall effectiveness of treatment program. Distinguishing between these two mechanisms has clinical implications since, if reduction of tumor burden is the mechanism by which salvage therapy improves survival, it might be advantageous to give more than two cycles of standard salvage chemotherapy prior to transplantation to maximally debulk the tumor. A prospective trial in which responders to salvage therapy were randomized to receive additional cycles of salvage therapy, or to proceed directly to transplantation, could help resolve this issue.
Recently, Stiff et al, 9 using chemotherapy regimens very similar to the regimens employed in this study, reported a 3-year survival of 55% in patients classified as having sensitive disease and 29% in patients classified as having chemoresistant relapse. They concluded that while intensified preparative therapy did not markedly improve results in patients with sensitive disease, for patients with resistant disease results were improved over historical controls treated with standard preparative therapy. While we achieved a similar survival following transplantation in patients with chemosensitive disease, we could not confirm the efficacy of intensified preparative therapy in chemoresistant disease. However, in our study, patients who failed an initial salvage regimen, and who responded to a later salvage regimen were considered responders to salvage therapy. In the study by Stiff et al, 9 these patients were classified as non-responders. Thus, it is not definitively established that intensified preparative therapy can improve results among patients with disease which is truly resistant to chemotherapy.
This study and other studies of intensified preparative regimens [10] [11] [12] have suggested, but have not proven, that such an approach improves survival following autologous transplantation. Apparent improvement in survival may be due to improvements in supportive care, better selection of patients, and more successful efforts to debulk tumor prior to autologous transplantation. Only large scale randomized trials can determine whether or not intensification of the preparative regimen can improve overall survival. However, the low treatment-related mortality of intensified preparative regimens justifies the use of this clinical approach in patients who respond to either initial or salvage therapy. For patients who fail to respond to initial or salvage therapy, alternative approaches such as newer salvage chemotherapy regimens or allogeneic transplantation could reasonably be studied.
